Cargando…

Bromfenac Ophthalmic Solution 0.07% Versus Nepafenac Ophthalmic Suspension 0.3% for Post-Cataract Surgery Inflammation: A Pilot Study of Identical Dosing Regimens with Pre-Surgical “Pulse” Dose

INTRODUCTION: This small pilot study is the first direct comparison of the currently marketed formulations of bromfenac (0.07% solution) and nepafenac (0.3% suspension) using identical dosing regimens and including an extra pre-surgical “pulse” dose in patients undergoing cataract surgery. METHODS:...

Descripción completa

Detalles Bibliográficos
Autor principal:	Silverstein, Steven M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2019
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6858409/ https://www.ncbi.nlm.nih.gov/pubmed/31552543 http://dx.doi.org/10.1007/s40123-019-00215-y

Ejemplares similares

In Vivo Pharmacokinetics of Bromfenac Ophthalmic Solution 0.075%, Bromfenac Ophthalmic Solution 0.07%, and Nepafenac/Amfenac Ophthalmic Suspension 0.3% in Rabbits
por: Sheppard, John D., et al.
Publicado: (2018)

Comparison of Once-Daily Bromfenac 0.07% Versus Once-Daily Nepafenac 0.3% in Patients Undergoing Phacoemulsification
por: Toyos, Melissa M.
Publicado: (2019)

The efficacy of bromfenac ophthalmic solution 0.07% dosed once daily in achieving zero-to-trace anterior chamber cell severity following cataract surgery
por: Silverstein, Steven M, et al.
Publicado: (2014)

The ocular distribution of (14)C-labeled bromfenac ophthalmic solution 0.07% in a rabbit model
por: Baklayan, George A, et al.
Publicado: (2014)

Topical ophthalmic NSAIDs: a discussion with focus on nepafenac ophthalmic suspension
por: Gaynes, Bruce I, et al.
Publicado: (2008)

Besifloxacin Ophthalmic Suspension 0.6% Compared with Gatifloxacin Ophthalmic Solution 0.3% for the Treatment of Bacterial Conjunctivitis in Neonates
por: Sanfilippo, Christine M., et al.
Publicado: (2017)

Efficacy of nepafenac ophthalmic suspension 0.1% in improving clinical outcomes following cataract surgery in patients with diabetes: an analysis of two randomized studies
por: Singh, Rishi P, et al.
Publicado: (2017)

Phase II placebo-controlled study of nepafenac ophthalmic suspension 0.1% for postoperative inflammation and ocular pain associated with cataract surgery in Japanese patients
por: Numaga, Jiro
Publicado: (2011)

Comparison of once daily dose of 0.3% nepafenac alone and three times dose of 0.1% nepafenac alone in pain and inflammation control after phacoemulsification
por: Bardoloi, Narayan, et al.
Publicado: (2022)

Ophthalmic nepafenac use in the Netherlands and Denmark
por: Margulis, Andrea V, et al.
Publicado: (2017)

Dose Uniformity of Loteprednol Etabonate (Submicron) Ophthalmic Gel 0.38% Compared with Prednisolone Acetate Ophthalmic Suspension 1%
por: Marlowe, Zora T., et al.
Publicado: (2021)

Evaluation of analgesic efficacy of bromfenac sodium ophthalmic solution 0.09% versus ketorolac tromethamine ophthalmic solution 0.5% following LASEK or Epi-LASIK
por: Wang, Xiao Jing, et al.
Publicado: (2011)

Safety of Besifloxacin Ophthalmic Suspension 0.6% in Cataract and LASIK Surgery Patients
por: Majmudar, Parag A., et al.
Publicado: (2014)

Management of ocular inflammation and pain following cataract surgery: focus on bromfenac ophthalmic solution
por: Cho, Hyung, et al.
Publicado: (2009)

Dose uniformity of loteprednol etabonate ophthalmic gel (0.5%) compared with branded and generic prednisolone acetate ophthalmic suspension (1%)
por: Marlowe, Zora T, et al.
Publicado: (2014)

Comparison of Drug Concentrations in Human Aqueous Humor after the Administration of 0.3% Gatifloxacin Ophthalmic Gel, 0.3% Gatifloxacin and 0.5% Levofloxacin Ophthalmic Solutions
por: Ding, Wenting, et al.
Publicado: (2015)

Dose uniformity of topical corticosteroid preparations: difluprednate ophthalmic emulsion 0.05% versus branded and generic prednisolone acetate ophthalmic suspension 1%
por: Stringer, William, et al.
Publicado: (2010)

Comparison of bromfenac 0.09% QD to nepafenac 0.1% TID after cataract surgery: pilot evaluation of visual acuity, macular volume, and retinal thickness at a single site
por: Cable, Melissa
Publicado: (2012)

Calculation of absorbed dose at 0.07-, 3.0- and 10.0-mm- depths in a slab phantom for monoenergetic electrons
por: Hirayama, H
Publicado: (1993)

A Case of Allergic Urticaria After Ophthalmic Nepafenac Use
por: Yaşar, Erdoğan, et al.
Publicado: (2018)

Real-World Use of Loteprednol Etabonate 0.5%/Tobramycin 0.3% Ophthalmic Suspension for the Treatment of Ocular Surface Inflammatory Conditions
por: Deom, James E, et al.
Publicado: (2022)

Efficacy of Topical Nepafenac 0.3% in the Management of Postoperative Cystoid Macular Edema
por: Giarmoukakis, Athanassios K, et al.
Publicado: (2020)

Besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis patients with Pseudomonas aeruginosa infections
por: Silverstein, Bruce E, et al.
Publicado: (2012)

Analgesic and anti-inflammatory effectiveness of nepafenac 0.1% for cataract surgery
por: Nardi, M, et al.
Publicado: (2007)

Bimatoprost 0.03%/timolol 0.5% preservative-free ophthalmic solution versus bimatoprost 0.03%/timolol 0.5% ophthalmic solution (Ganfort) for glaucoma or ocular hypertension: a 12-week randomised controlled trial
por: Goldberg, Ivan, et al.
Publicado: (2014)

Tuning of the Structure and Magnetocaloric Effect of Mn(1−x)Zr(x)CoGe Alloys (Where x = 0.03, 0.05, 0.07, and 0.1)
por: Kutynia, Karolina, et al.
Publicado: (2021)

Personal dose equivalent H(p)(0.07) during (68)Ga-DOTA-TATE production procedures
por: Wrzesień, M., et al.
Publicado: (2023)

Bimatoprost 0.03% preservative-free ophthalmic solution versus bimatoprost 0.03% ophthalmic solution (Lumigan) for glaucoma or ocular hypertension: a 12-week, randomised, double-masked trial
por: Day, Douglas G, et al.
Publicado: (2013)

Thermal activation energy of 3D vortex matter in NaFe(1−x)Co(x)As (x = 0.01, 0.03 and 0.07) single crystals
por: Choi, W. J., et al.
Publicado: (2017)

Effect of storage temperature on the dispersibility of commercially available 0.1% fluorometholone ophthalmic suspension
por: Obata, Tokio, et al.
Publicado: (2022)

The Effect of Substitution of Mn by Pd on the Structure and Thermomagnetic Properties of the Mn(1−x)Pd(x)CoGe Alloys (Where x = 0.03, 0.05, 0.07 and 0.1)
por: Kutynia, Karolina, et al.
Publicado: (2023)

Comparison of preoperative nepafenac (0.1%) and flurbiprofen (0.03%) eye drops in maintaining mydriasis during small incision cataract surgery in patients with senile cataract: A randomized, double-blind study
por: Sarkar, Saumya, et al.
Publicado: (2015)

Bromfenac ophthalmic solution for the treatment of postoperative ocular pain and inflammation: safety, efficacy, and patient adherence
por: Rajpal, Rajesh K, et al.
Publicado: (2014)

The Effects of Two Non-Steroidal Anti-Inflammatory Drugs, Bromfenac 0.1% and Ketorolac 0.45%, on Cataract Surgery
por: Jung, Ji Won, et al.
Publicado: (2015)

Comparison of effect of nepafenac and diclofenac ophthalmic solutions on cornea, tear film, and ocular surface after cataract surgery: the results of a randomized trial
por: Kawahara, Atsushi, et al.
Publicado: (2016)

Effect of 0.1% Bromfenac for Preventing Macular Edema after Cataract Surgery in Patients with Diabetes
por: Song, Seok Hyeon, et al.
Publicado: (2020)

Loteprednol etabonate ophthalmic suspension 0.5 %: efficacy and safety for postoperative anti-inflammatory use
por: Amon, Michael, et al.
Publicado: (2012)

A retrospective analysis of the use of loteprednol etabonate ophthalmic suspension 0.5% following canaloplasty
por: Khaimi, Mahmoud A
Publicado: (2018)

Tuning Magnetic Entropy Change and Relative Cooling Power in La(0.7)Ca(0.23)Sr(0.07)MnO(3) Electrospun Nanofibers
por: Burrola Gándara, Luis Andrés, et al.
Publicado: (2020)

Manipulating magnetoelectric properties by interfacial coupling in La(0.3)Sr(0.7)MnO(3)/Ba(0.7)Sr(0.3)TiO(3) superlattices
por: Guo, Haizhong, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_gu90h84t5t1d179a9ho8mbik2i